SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171-2177.
  • 2
    Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859-866.
  • 3
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005;482:202-205.
  • 4
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol. 2005;482:189-199.
  • 5
    Ruggeri EM, Giannarelli D, Bria E, et al. Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. Cancer. 2006;106:783-788.
  • 6
    Meeks JJ, Bellmunt J, Bochner BH, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012;62:523-533.
  • 7
    Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol. 2012;23:695-700.
  • 8
    Paz-Ares LG, Solsona E, Esteban E, et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group 99/01 study. J Clin Oncol. 2010;28.
  • 9
    European Organization for Research and Treatment of Cancer. Randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4, and/or N+M0 transitional cell carcinoma (TCC) of the bladder. EORTC Trial 30994, ed. Available at: http://www.eortc.be/clinicaltrials/details.asp?protocol=30994. Accessed May 9, 2013.
  • 10
    Mackillop WJ. Health services research in radiation oncology: toward achieving the achievable. In: Gunderson LL, Tepper JE, eds. Clinical Radiation Oncology. Philadelphia: Churchill Livingstone; 2007:215-237.
  • 11
    Meyer RM. Generalizing the results of cancer clinical trials. J Clin Oncol. 2010;28:187-189.
  • 12
    Booth CM, Mackillop WJ. Translating new medical therapies into societal benefit: the role of population-based outcome studies. JAMA. 2008;300:2177-2179.
  • 13
    Clarke EA, Marrett LD, Krieger N. Cancer registration in Ontario: a computer approach. In: Jenson OM, Parkin DM, MacLennan R, eds. Cancer Registration Principles and Methods. Lyon, France: IARC, 1991:246-257.
  • 14
    Booth CM, Li G, Zhang-Salomons J, Mackillop WJ. The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada. Cancer. 2010.
  • 15
    Williams J, Young W. A summary of studies on the quality of health care administrative databases in Canada. In: Goel V, Williams JI, Anderson GM, et al, eds. Patterns of Health Care in Ontario: The ICES Practice Atlas. Ottawa, Ontario, Canada: Canadian Medical Association,;1996:339-345.
  • 16
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
  • 17
    Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001;19:1064-1070.
  • 18
    Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-763.
  • 19
    Winquist E, Waldron T, Segal R, Chin J, Likka H. Use of neoadjuvant chemotherapy in transitional cell carcinoma of the bladder Practice Guideline Report #3-2-2. Cancer Care Ontario Program in Evidence-Based Care, ed. Available at: https://www.cancercare.on.ca/toolbox/qualityguidelines/diseasesite/genito-ebs/. Accessed May 9, 2013.
  • 20
    Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007;69(1 Suppl):62-79.
  • 21
    Segal R, Winquist E, Lukka H, et al. Use of Adjuvant Chemotherapy Following Cystectomy in Patients with Deep Muscle-Invasive Transitional Cell Carcinoma of the Bladder.
  • 22
    Practice Guideline Report #3-2-1. Cancer Care Ontario Program in Evidence-Based Care, ed. Available at: https://www.cancercare.on.ca/toolbox/qualityguidelines/diseasesite/genito-ebs/. Accessed May 9, 2013.
  • 23
    Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol. 2002;3:738-747.
  • 24
    David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007;178:451-454.
  • 25
    Schrag D, Mitra N, Xu F, et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology. 2005;65:1118-1125.
  • 26
    Porter MP, Kerrigan MC, Donato BMK, et al. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol. 2011;29:252-258.
  • 27
    Svatek RS, Shariat SF, Lasky RE, et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010;16:4461-4467.
  • 28
    Goossens-Laan CA, Gooiker GA, van GW, et al. A systematic review and meta-analysis of the relationship between hospital/surgeon volume and outcome for radical cystectomy: an update for the ongoing debate. Eur Urol. 2011;59:775-783.
  • 29
    Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351543-551.
  • 30
    Booth CM, Shepherd FA, Peng Y, et al. Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. J Clin Oncol. 2010;28:3472-3478.